Positive News SentimentPositive NewsNASDAQ:HRMY Harmony Biosciences (HRMY) Stock Price, News & Analysis $35.59 +0.03 (+0.08%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$35.17▼$35.9950-Day Range$30.00▼$36.8052-Week Range$18.61▼$39.26Volume304,886 shsAverage Volume373,038 shsMarket Capitalization$2.02 billionP/E Ratio15.41Dividend YieldN/APrice Target$41.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Harmony Biosciences alerts: Email Address Harmony Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside11.0% Upside$39.50 Price TargetShort InterestBearish28.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth59.36%From $2.19 to $3.49 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.27 out of 5 starsMedical Sector292nd out of 910 stocksPharmaceutical Preparations Industry124th out of 426 stocks 2.3 Analyst's Opinion Consensus RatingHarmony Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, no hold ratings, and 2 sell ratings.Amount of Analyst CoverageHarmony Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Harmony Biosciences' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted28.46% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 24, which indicates bearish sentiment.Change versus previous monthShort interest in Harmony Biosciences has recently increased by 3.93%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HRMY. Previous Next 3.3 News and Social Media Coverage News SentimentHarmony Biosciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Harmony Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for HRMY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders30.80% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harmony Biosciences' insider trading history. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 59.36% in the coming year, from $2.19 to $3.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 15.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 15.41, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.06.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.72. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 3.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harmony Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Harmony Biosciences Stock (NASDAQ:HRMY)Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Read More HRMY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HRMY Stock News HeadlinesAugust 28, 2024 | americanbankingnews.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives $41.67 Consensus Target Price from AnalystsAugust 25, 2024 | msn.comHarmony Biosciences Set to Engage at Key Investor ConferencesSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 21, 2024 | prnewswire.comHARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCESAugust 19, 2024 | seekingalpha.comHarmony Biosciences: Unnoticed Melodies Of Portfolio Growth And Pipeline PotentialAugust 15, 2024 | seekingalpha.comHarmony Biosciences: Advancing An Expanded PipelineAugust 7, 2024 | msn.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2024 Earnings Call TranscriptAugust 7, 2024 | markets.businessinsider.comHarmony Biosciences Holdings Sell Rating Affirmed Amid Slowing Patient Growth and Unchanged Revenue GuidanceSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 6, 2024 | msn.comUpdate: OLPX, HRMY, GLDD and III, August 6August 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Harmony Biosciences on Strong Earnings and Promising Drug Formulation ProspectsAugust 6, 2024 | seekingalpha.comHarmony Biosciences Holdings, Inc. (HRMY) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | seekingalpha.comHarmony Biosciences Holdings, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 6, 2024 | globenewswire.comHarmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028August 5, 2024 | markets.businessinsider.comHarmony Biosciences earnings preview: what to expectJuly 29, 2024 | msn.comHarmony Biosciences to Announce Q2 Financial ResultsJuly 27, 2024 | msn.comPortfolio Change: One Stock To Buy, July 26July 24, 2024 | finance.yahoo.comHarmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Stock Is Going Strong: Is the Market Following Fundamentals?See More Headlines Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HRMY CUSIPN/A CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$39.50 High Stock Price Target$52.00 Low Stock Price Target$27.00 Potential Upside/Downside+17.1%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$2.31 Trailing P/E Ratio15.41 Forward P/E Ratio16.25 P/E Growth0.72Net Income$128.85 million Net Margins17.53% Pretax Margin25.15% Return on Equity22.97% Return on Assets13.96% Debt Debt-to-Equity Ratio0.32 Current Ratio3.13 Quick Ratio3.09 Sales & Book Value Annual Sales$656.11 million Price / Sales3.08 Cash Flow$2.58 per share Price / Cash Flow13.79 Book Value$9.48 per share Price / Book3.75Miscellaneous Outstanding Shares56,792,000Free Float39,300,000Market Cap$2.02 billion OptionableOptionable Beta0.73 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Jeffrey S. Aronin (Age 56)Founder & Non-Executive Chairman Comp: $185.67kDr. Jeffrey M. Dayno M.D. (Age 67)President, CEO & Director Comp: $1.26MMr. Sandip S. Kapadia CPA (Age 54)M.B.A., Executive VP, Chief Administrative Officer & CFO Comp: $813.52kMr. David BradshawHead of Technical OperationsLuis SanayHead of Investor RelationsMr. Christian UlrichGeneral Counsel & Corporate SecretaryMs. Tricia GloverChief Compliance OfficerMs. Audrey Murphy SPHRVice Presidet of Human ResourcesMs. Cate McCanlessHead of Corporate Affairs & Public PolicyMs. Kelli WrightSenior Manager of Patient Advocacy & Harmony BiosciencesMore ExecutivesKey CompetitorsAimmune TherapeuticsNASDAQ:AIMTRa PharmaceuticalsNASDAQ:RARXTaro Pharmaceutical IndustriesNYSE:TAROOPKO HealthNASDAQ:OPKXencorNASDAQ:XNCRView All CompetitorsInsiders & InstitutionsCim LLCBought 1,705 shares on 9/6/2024Ownership: 0.024%Algert Global LLCSold 25,000 shares on 8/16/2024Ownership: 0.181%Quarry LPBought 2,052 shares on 8/16/2024Ownership: 0.004%AXA S.A.Sold 856 shares on 8/15/2024Ownership: 0.065%The Manufacturers Life Insurance Company Sold 477 shares on 8/15/2024Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions HRMY Stock Analysis - Frequently Asked Questions How have HRMY shares performed this year? Harmony Biosciences' stock was trading at $32.30 on January 1st, 2024. Since then, HRMY shares have increased by 10.2% and is now trading at $35.59. View the best growth stocks for 2024 here. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) released its earnings results on Tuesday, August, 6th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.24. The firm's quarterly revenue was up 28.8% compared to the same quarter last year. When did Harmony Biosciences IPO? Harmony Biosciences (HRMY) raised $101 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO. Who are Harmony Biosciences' major shareholders? Harmony Biosciences' top institutional investors include Pacer Advisors Inc. (4.42%), Dimensional Fund Advisors LP (1.68%), American Century Companies Inc. (1.20%) and Renaissance Technologies LLC (1.05%). Insiders that own company stock include Jack Nielsen, Andreas Wicki, John C Jacobs, Jeffrey M Dayno and Jeffrey Dierks. View institutional ownership trends. How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge Global (BG), Carrier Global (CARR) and Commercial Metals (CMC). This page (NASDAQ:HRMY) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free hrmy Stock Alerts